Pentraxin 3 might be better prognostic serum marker than IL-6, IL-10, and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation

Farid Ljuca; Bahrudin Hadžiefendić; Elmir Jahić; Nijaz Tihić; Saša Lukić

doi:10.15537/smj.2019.12.24737

References

↵
1. Kunes P,
2. Holubcova Z,
3. Kolackova M,
4. Krejsek J
(2012) Pentraxin 3 (PTX 3):an endogenous modulator of the inflammatory response. Mediators Inflamm 2012:10.
OpenUrl
↵
1. Momiyama Y,
2. Kawaguchi A,
3. Kajiwara I,
4. Ohmori R,
5. Okada K,
6. Saito I,
7. et al.
(2009) Prognostic value of plasma high-sensitivity c-reactive protein levels in Japanese patients with stable coronary artery disease:the Japan NCVC-collaborative inflammation cohort (JNIC) Study. Atherosclerosis 207:272–276.
OpenUrl CrossRef PubMed Web of Science
1. Jenny NS,
2. Arnold AM,
3. Kuller LH,
4. Tracy RP,
5. Psaty BM
(2009) Associations of pentraxin 3 with cardiovascular disease and all-cause death:The cardiovascular health study. Arterioscler Thromb Vasc Biol 29:594–599.
OpenUrl Abstract/FREE Full Text
1. Latini R,
2. Maggioni AP,
3. Peri G,
4. Gonzini L,
5. Lucci D,
6. Mocarelli P,
7. et al.
(2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110:2349–2354.
OpenUrl Abstract/FREE Full Text
↵
1. Inoue T,
2. Kato T,
3. Uchida T,
4. Sakuma M,
5. Nakajima A,
6. Shibazaki M,
7. et al.
(2005) Local release of c-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 46:239–245.
OpenUrl FREE Full Text
↵
1. Gottsauner-Wolf M,
2. Zasmeta G,
3. Hornykewycz S,
4. Nikfardjam M,
5. Stepan E,
6. Wexberg P,
7. et al.
(2000) Plasma levels of c-reactive protein after coronary stent implantation. Eur Heart J 21:1152–1158.
OpenUrl CrossRef PubMed Web of Science
↵
1. Munk PS,
2. Breland UM,
3. Aukrust P,
4. Skadberg O,
5. Ueland T,
6. Larsen AI
(2011) Inflammatory response to percutaneous coronary intervention in stable coronary artery disease. J Thromb Thrombolysis 31:92–98.
OpenUrl CrossRef PubMed
↵
1. Kotooka N,
2. Inoue T,
3. Fujimatsu D,
4. Morooka T,
5. Hashimoto S,
6. Hikichi Y,
7. et al.
(2008) Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 197:368–374.
OpenUrl CrossRef PubMed Web of Science
↵
1. Hudzik B,
2. Szkodzinski J,
3. Pietka-Rzycka A,
4. Danikiewicz A,
5. Wojnar R,
6. Lekston A,
7. et al.
(2013) Plasma pentraxin 3 may be a more sensitive marker of inflammatory response than high-sensitivity C-reactive protein after bare metal stent compared to drug-eluting stent implantation. J Interferon Cytokine Res 33:280–284.
OpenUrl CrossRef PubMed Web of Science
↵
1. Haibo L,
2. Xiaofang G,
3. Chunming W,
4. Jie Y,
5. Guozhong C,
6. Limei Z,
7. et al.
(2014) Prognostic value of Plasma pentraxin 3 level in patients with stable coronary artery disease after drug-eluted stent implantation. Mediators Inflamm 2014:963096.
OpenUrl
↵
1. Chen SL,
2. Liu Y,
3. Lin L,
4. Ye F,
5. Zhang JJ,
6. Tian NL,
7. et al.
(2014) Interleukin-6, but not C-reactive protein, predicts the occurrence of cardiovascular events after drug-eluting stent for unstable angina. J Interv Cardiol 27:142–154.
OpenUrl
↵
1. Groot HE,
2. Al Ali L,
3. van der Horst ICC,
4. Schurer RAJ,
5. van der Werf HW,
6. Lipsic E,
7. et al.
(2019) Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. Clin Res Cardiol 108:612–621.
OpenUrl
↵
1. Hwang SJ,
2. Park KW,
3. Kwon DA,
4. Kang HJ,
5. Koo BK,
6. Chae IH,
7. et al.
(2011) High plasma interleukin-6 is associated with drug-eluting stent thrombosis:possible role of inflammatory cytokines in the development of stent thrombosis from the Korea Stent Thrombosis Registry. Circ J 75:1350–1357.
OpenUrl CrossRef PubMed
↵
1. Monraats PS,
2. Kurreeman FA,
3. Pons Det al
(2007) Interleukin 10:a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun 8:44–50.
OpenUrl CrossRef PubMed
↵
1. Monraats PS,
2. Kurreeman FA,
3. Pons D,
4. Sewgobind VD,
5. de Vries FR,
6. Zwinderman AH,
7. et al.
(2013) Plasma levels of interleukin 18, interleukin 10, and matrix metalloproteinase-9 and -137G/C polymorphism of interleukin 18 are associated with incidence of in-stent restenosis after percutaneous coronary intervention. Genes Immun 36:1129–1135.
OpenUrl
↵
1. Tomandlova M,
2. Jarkovskyv J,
3. Tomandl J,
4. Kubkova L,
5. Kala P,
6. Littnerova S,
7. et al.
(2015) Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress. Dis Markers 2015:1–11.
OpenUrl PubMed
↵
1. Akgul O,
2. Baycan OF,
3. Bulut U,
4. Somuncu MU,
5. Pusuroglu H,
6. Ozyilmaz S,
7. Gul M,
8. et al.
(2015) Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Coron Artery Dis 26:592–597.
OpenUrl
↵
1. Latini R,
2. Maggioni AP,
3. Peri G,
4. Gonzini L,
5. Lucci D,
6. Mocarelli P,
7. et al.
(2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110:2349–2354.
OpenUrl Abstract/FREE Full Text
↵
1. Helseth R,
2. Solheim S,
3. Opstad T,
4. Hoffmann P,
5. Arnesen H,
6. Seljeflot I
(2014) The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention. Mediators Inflamm 2014:608414.
OpenUrl
↵
1. Guo R,
2. Li Y,
3. Wen J,
4. Li W,
5. Xu Y
(2014) Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST segment elevation myocardial infarction who have undergone percutaneous coronary intervention. Cardiology 129:178–188.
OpenUrl
↵
1. Matsui S,
2. Ishii J,
3. Kitagawa F,
4. Kuno A,
5. Hattori K,
6. Ishikawa M,
7. et al.
(2010) Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 210:220–225.
OpenUrl CrossRef PubMed Web of Science
↵
1. Palmerini T,
2. Biondi-Zoccai G,
3. Della Riva D,
4. Stettler C,
5. Sangiorgi D,
6. D'Ascenzo F,
7. et al.
(2012) Stent thrombosis with drug-eluting and bare-metal stents:evidence from a comprehensive network meta-analysis. Lancet 379:1393–1402.
OpenUrl CrossRef PubMed Web of Science
↵
1. Hall TS,
2. Hallén J,
3. Krucoff MW,
4. Roe MT,
5. Brennan DM,
6. Agewall S,
7. et al.
(2015) Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. A m Heart J 169:257–265.
OpenUrl
↵
1. Feldman DN,
2. Kim L,
3. Rene AG,
4. Minutello RM,
5. Bergman G,
6. Wong SC
(2011) Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention:a meta-analysis. Catheter Cardiovasc Interv 77:1020–1030.
OpenUrl CrossRef PubMed
↵
1. Feldman DN,
2. Minutello RM,
3. Bergman G,
4. Moussa I,
5. Wong SC
(2009) Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes. Am J Cardiol 104:1210–1215.
OpenUrl CrossRef PubMed

In this issue

Download PDF

Email Article

Citation Tools

Bookmark this article

Cited By...

Predictors on outcomes of cardiovascular disease of male patients in Malaysia using Bayesian network analysis

Google Scholar

More in this TOC Section

Show more Original Article

[1] ↵
Kunes P,
Holubcova Z,
Kolackova M,
Krejsek J
(2012) Pentraxin 3 (PTX 3):an endogenous modulator of the inflammatory response. Mediators Inflamm 2012:10.
OpenUrl

[2] Kunes P,

[3] Holubcova Z,

[4] Kolackova M,

[5] Krejsek J

[6] ↵
Momiyama Y,
Kawaguchi A,
Kajiwara I,
Ohmori R,
Okada K,
Saito I,
et al.
(2009) Prognostic value of plasma high-sensitivity c-reactive protein levels in Japanese patients with stable coronary artery disease:the Japan NCVC-collaborative inflammation cohort (JNIC) Study. Atherosclerosis 207:272–276.
OpenUrl CrossRef PubMed Web of Science

[7] Momiyama Y,

[8] Kawaguchi A,

[9] Kajiwara I,

[10] Ohmori R,

[11] Okada K,

[12] Saito I,

[13] et al.

[14] Jenny NS,
Arnold AM,
Kuller LH,
Tracy RP,
Psaty BM
(2009) Associations of pentraxin 3 with cardiovascular disease and all-cause death:The cardiovascular health study. Arterioscler Thromb Vasc Biol 29:594–599.
OpenUrl Abstract/FREE Full Text

[15] Jenny NS,

[16] Arnold AM,

[17] Kuller LH,

[18] Tracy RP,

[19] Psaty BM

[20] Latini R,
Maggioni AP,
Peri G,
Gonzini L,
Lucci D,
Mocarelli P,
et al.
(2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110:2349–2354.
OpenUrl Abstract/FREE Full Text

[21] Latini R,

[22] Maggioni AP,

[23] Peri G,

[24] Gonzini L,

[25] Lucci D,

[26] Mocarelli P,

[27] et al.

[28] ↵
Inoue T,
Kato T,
Uchida T,
Sakuma M,
Nakajima A,
Shibazaki M,
et al.
(2005) Local release of c-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 46:239–245.
OpenUrl FREE Full Text

[29] Inoue T,

[30] Kato T,

[31] Uchida T,

[32] Sakuma M,

[33] Nakajima A,

[34] Shibazaki M,

[35] et al.

[36] ↵
Gottsauner-Wolf M,
Zasmeta G,
Hornykewycz S,
Nikfardjam M,
Stepan E,
Wexberg P,
et al.
(2000) Plasma levels of c-reactive protein after coronary stent implantation. Eur Heart J 21:1152–1158.
OpenUrl CrossRef PubMed Web of Science

[37] Gottsauner-Wolf M,

[38] Zasmeta G,

[39] Hornykewycz S,

[40] Nikfardjam M,

[41] Stepan E,

[42] Wexberg P,

[43] et al.

[44] ↵
Munk PS,
Breland UM,
Aukrust P,
Skadberg O,
Ueland T,
Larsen AI
(2011) Inflammatory response to percutaneous coronary intervention in stable coronary artery disease. J Thromb Thrombolysis 31:92–98.
OpenUrl CrossRef PubMed

[45] Munk PS,

[46] Breland UM,

[47] Aukrust P,

[48] Skadberg O,

[49] Ueland T,

[50] Larsen AI

[51] ↵
Kotooka N,
Inoue T,
Fujimatsu D,
Morooka T,
Hashimoto S,
Hikichi Y,
et al.
(2008) Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 197:368–374.
OpenUrl CrossRef PubMed Web of Science

[52] Kotooka N,

[53] Inoue T,

[54] Fujimatsu D,

[55] Morooka T,

[56] Hashimoto S,

[57] Hikichi Y,

[58] et al.

[59] ↵
Hudzik B,
Szkodzinski J,
Pietka-Rzycka A,
Danikiewicz A,
Wojnar R,
Lekston A,
et al.
(2013) Plasma pentraxin 3 may be a more sensitive marker of inflammatory response than high-sensitivity C-reactive protein after bare metal stent compared to drug-eluting stent implantation. J Interferon Cytokine Res 33:280–284.
OpenUrl CrossRef PubMed Web of Science

[60] Hudzik B,

[61] Szkodzinski J,

[62] Pietka-Rzycka A,

[63] Danikiewicz A,

[64] Wojnar R,

[65] Lekston A,

[66] et al.

[67] ↵
Haibo L,
Xiaofang G,
Chunming W,
Jie Y,
Guozhong C,
Limei Z,
et al.
(2014) Prognostic value of Plasma pentraxin 3 level in patients with stable coronary artery disease after drug-eluted stent implantation. Mediators Inflamm 2014:963096.
OpenUrl

[68] Haibo L,

[69] Xiaofang G,

[70] Chunming W,

[71] Jie Y,

[72] Guozhong C,

[73] Limei Z,

[74] et al.

[75] ↵
Chen SL,
Liu Y,
Lin L,
Ye F,
Zhang JJ,
Tian NL,
et al.
(2014) Interleukin-6, but not C-reactive protein, predicts the occurrence of cardiovascular events after drug-eluting stent for unstable angina. J Interv Cardiol 27:142–154.
OpenUrl

[76] Chen SL,

[77] Liu Y,

[78] Lin L,

[79] Ye F,

[80] Zhang JJ,

[81] Tian NL,

[82] et al.

[83] ↵
Groot HE,
Al Ali L,
van der Horst ICC,
Schurer RAJ,
van der Werf HW,
Lipsic E,
et al.
(2019) Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. Clin Res Cardiol 108:612–621.
OpenUrl

[84] Groot HE,

[85] Al Ali L,

[86] van der Horst ICC,

[87] Schurer RAJ,

[88] van der Werf HW,

[89] Lipsic E,

[90] et al.

[91] ↵
Hwang SJ,
Park KW,
Kwon DA,
Kang HJ,
Koo BK,
Chae IH,
et al.
(2011) High plasma interleukin-6 is associated with drug-eluting stent thrombosis:possible role of inflammatory cytokines in the development of stent thrombosis from the Korea Stent Thrombosis Registry. Circ J 75:1350–1357.
OpenUrl CrossRef PubMed

[92] Hwang SJ,

[93] Park KW,

[94] Kwon DA,

[95] Kang HJ,

[96] Koo BK,

[97] Chae IH,

[98] et al.

[99] ↵
Monraats PS,
Kurreeman FA,
Pons Det al
(2007) Interleukin 10:a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun 8:44–50.
OpenUrl CrossRef PubMed

[100] Monraats PS,

[101] Kurreeman FA,

[102] Pons Det al

[103] ↵
Monraats PS,
Kurreeman FA,
Pons D,
Sewgobind VD,
de Vries FR,
Zwinderman AH,
et al.
(2013) Plasma levels of interleukin 18, interleukin 10, and matrix metalloproteinase-9 and -137G/C polymorphism of interleukin 18 are associated with incidence of in-stent restenosis after percutaneous coronary intervention. Genes Immun 36:1129–1135.
OpenUrl

[104] Monraats PS,

[105] Kurreeman FA,

[106] Pons D,

[107] Sewgobind VD,

[108] de Vries FR,

[109] Zwinderman AH,

[110] et al.

[111] ↵
Tomandlova M,
Jarkovskyv J,
Tomandl J,
Kubkova L,
Kala P,
Littnerova S,
et al.
(2015) Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress. Dis Markers 2015:1–11.
OpenUrl PubMed

[112] Tomandlova M,

[113] Jarkovskyv J,

[114] Tomandl J,

[115] Kubkova L,

[116] Kala P,

[117] Littnerova S,

[118] et al.

[119] ↵
Akgul O,
Baycan OF,
Bulut U,
Somuncu MU,
Pusuroglu H,
Ozyilmaz S,
Gul M,
et al.
(2015) Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Coron Artery Dis 26:592–597.
OpenUrl

[120] Akgul O,

[121] Baycan OF,

[122] Bulut U,

[123] Somuncu MU,

[124] Pusuroglu H,

[125] Ozyilmaz S,

[126] Gul M,

[127] et al.

[128] ↵
Latini R,
Maggioni AP,
Peri G,
Gonzini L,
Lucci D,
Mocarelli P,
et al.
(2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110:2349–2354.
OpenUrl Abstract/FREE Full Text

[129] Latini R,

[130] Maggioni AP,

[131] Peri G,

[132] Gonzini L,

[133] Lucci D,

[134] Mocarelli P,

[135] et al.

[136] ↵
Helseth R,
Solheim S,
Opstad T,
Hoffmann P,
Arnesen H,
Seljeflot I
(2014) The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention. Mediators Inflamm 2014:608414.
OpenUrl

[137] Helseth R,

[138] Solheim S,

[139] Opstad T,

[140] Hoffmann P,

[141] Arnesen H,

[142] Seljeflot I

[143] ↵
Guo R,
Li Y,
Wen J,
Li W,
Xu Y
(2014) Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST segment elevation myocardial infarction who have undergone percutaneous coronary intervention. Cardiology 129:178–188.
OpenUrl

[144] Guo R,

[145] Li Y,

[146] Wen J,

[147] Li W,

[148] Xu Y

[149] ↵
Matsui S,
Ishii J,
Kitagawa F,
Kuno A,
Hattori K,
Ishikawa M,
et al.
(2010) Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 210:220–225.
OpenUrl CrossRef PubMed Web of Science

[150] Matsui S,

[151] Ishii J,

[152] Kitagawa F,

[153] Kuno A,

[154] Hattori K,

[155] Ishikawa M,

[156] et al.

[157] ↵
Palmerini T,
Biondi-Zoccai G,
Della Riva D,
Stettler C,
Sangiorgi D,
D'Ascenzo F,
et al.
(2012) Stent thrombosis with drug-eluting and bare-metal stents:evidence from a comprehensive network meta-analysis. Lancet 379:1393–1402.
OpenUrl CrossRef PubMed Web of Science

[158] Palmerini T,

[159] Biondi-Zoccai G,

[160] Della Riva D,

[161] Stettler C,

[162] Sangiorgi D,

[163] D'Ascenzo F,

[164] et al.

[165] ↵
Hall TS,
Hallén J,
Krucoff MW,
Roe MT,
Brennan DM,
Agewall S,
et al.
(2015) Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. A m Heart J 169:257–265.
OpenUrl

[166] Hall TS,

[167] Hallén J,

[168] Krucoff MW,

[169] Roe MT,

[170] Brennan DM,

[171] Agewall S,

[172] et al.

[173] ↵
Feldman DN,
Kim L,
Rene AG,
Minutello RM,
Bergman G,
Wong SC
(2011) Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention:a meta-analysis. Catheter Cardiovasc Interv 77:1020–1030.
OpenUrl CrossRef PubMed

[174] Feldman DN,

[175] Kim L,

[176] Rene AG,

[177] Minutello RM,

[178] Bergman G,

[179] Wong SC

[180] ↵
Feldman DN,
Minutello RM,
Bergman G,
Moussa I,
Wong SC
(2009) Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes. Am J Cardiol 104:1210–1215.
OpenUrl CrossRef PubMed

[181] Feldman DN,

[182] Minutello RM,

[183] Bergman G,

[184] Moussa I,

[185] Wong SC

Main menu

User menu

Search

Pentraxin 3 might be better prognostic serum marker than IL-6, IL-10, and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

CONTENT

JOURNAL

AUTHORS

Main menu

User menu

Search

Pentraxin 3 might be better prognostic serum marker than IL-6, IL-10, and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

CONTENT

JOURNAL

AUTHORS